All In MedTech

FDA Clearance Tracker · P930039-S107

MEDTRONIC CAPSUREFIX NOVUS MRI SURESCAN MODEL 5076 LEAD

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 13, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 13, 2014

Approved

Time to decision

179 days

Received Apr 17, 2014. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P930039-S107
Device name
MEDTRONIC CAPSUREFIX NOVUS MRI SURESCAN MODEL 5076 LEAD
Applicant location
Mounds View, MN
Received
Apr 17, 2014
Decided
Oct 13, 2014
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P930039

Device type

Device class
Class III

Every decision under product code NVN

FDA's approval statement

As written in FDA's record.

APPROVAL FOR ADDING THE 5076 CAPSUREFIX NOVUS LEAD TO THE MR CONDITIONALPACING FAMILY. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME CAPSUREFIX NOVUS MRI SURESCAN MODEL 5076 AND IS INDICATED FOR USE AS A SYSTEM CONSISTING OF A MEDTRONIC MRI SURESCAN IPG IMPLANTED WITH SURESCAN LEADS. A COMPLETE SYSTEM IS REQUIRED FOR USE IN THEMRI ENVIRONMENT.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.